MoneyWorks4Me

Trident Lifeline Ltd (543616)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543616 NSE: Pharmaceuticals & Drugs | Small Cap | Trident Lifeline Share Price

₹392.20 -12.55 (-3.10%)

As on 23-Sep'26 11:42

Trident Lifeline Ltd (543616)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543616 NSE: Pharmaceuticals & Drugs | Small Cap | Trident Lifeline Share Price

₹392.20 -12.55 (-3.10%)

As on 23-Sep'26 11:42

Key Metrics
Valuation Multiples
Market Cap
₹484 Cr.
Current Price
₹392.2
52-Week Low / High
₹230 / 421
TTM EPS
₹15.9
TTM Sales
₹129 Cr.
Book Value per Share
₹82.4
P/E Ratio
25.42
Lower than its 5-year historical median
Industry PE
54.8
Price to Book (P/B)
4.91
Higher than its 5-year historical median
Price to Sales (P/S)
3.75
Lower than its 5-year historical median
EV/EBITDA
14.46
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
18.78%
Outperforms industry median
Return on Capital Employed (ROCE)
19.17%
Outperforms industry median
Return on Assets (ROA)
8.64%
Operating Profit Margin
17.3%
Net Profit Margin
12.07%
Gross Profit Margin
22%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
51.85%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
82.5%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
76.6%
Asset Quality
Promoter Holding
62.59%
Pledged shares (%) of Promoter's holding (%)
6.93%
Reserves
₹89 Cr.
Equity
₹12 Cr.
Face Value
₹10
All Time Low / High
₹102.75 / 371.00

Trident Lifeline stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Overvalued

Price Trend

Weak
Q.1 Is Trident Lifeline Ltd a good quality company?
Trident Lifeline Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Trident Lifeline Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Trident Lifeline Ltd vs industry peers?
Trident Lifeline Ltd revenue CAGR is 58.67%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Trident Lifeline Ltd?
Promoters hold 62.59% of the Trident Lifeline Ltd, with 6.93% of their stake pledged, indicating low pledge risk.
Q.1 Stock return of Trident Lifeline Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 26.26% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Trident Lifeline Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -9.1%33.7%55.1%25.1%19.1%27.7%-
Value Creation
Index
NA1.42.90.80.41.0-

Growth Parameters

Sales 4.99.621.831.744.767.8102
Sales YoY Gr.-95.1%126.3%45.6%40.9%51.9%-
Adj EPS -2.61.24.95.1611.115.1
YoY Gr.-NA314.5%5.2%18.2%84.6%-
BVPS (₹) -9.7-0.9639.745.857.184.5
Adj Net
Profit
-0.80.63.95.96.912.818
Cash Flow from Ops. -0.61.5-0.2-16.60.9-3.5-
Debt/CF from Ops. -10.93.1-12.8-0.26.9-4.3-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NA68.9%46%51.9%
Adj EPS NANA31.9%84.6%
BVPSNANA112.3%24.8%
Share Price - - 26.3% 31.7%

Key Financial Parameters

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
27.1-33.6180.323.314.121.621.4
Op. Profit
Mgn %
-5.51312.419.819.926.125.6
Net Profit
Mgn %
-16.56.117.818.515.518.917.8
Debt to
Equity
-2.2-9.60.50.10.10.2-
Working Cap
Days
022316426735532678
Cash Conv.
Cycle
030339511810246

Valuation of Trident Lifeline - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *1.760.000.003.463.463.463.436.776.906.93
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales22324587
Operating Expenses + 19253672
Manufacturing Costs55712
Material Costs11162537
Employee Cost 11211
Other Costs 33312
Operating Profit 36815
Operating Profit Margin (%) 12.4%19.8%18.5%17.3%
Other Income + 1128
Exceptional Items 0000
Interest 0014
Depreciation 0015
Profit Before Tax 37914
Tax -1133
Profit After Tax 46610
PAT Margin (%) 18.1%19.0%13.3%12.1%
Adjusted EPS (₹)4.95.25.510.2
Dividend Payout Ratio (%)0%0%0%0%
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 5465264
Share Capital 8111111
Reserves -3344053
Debt +261749
Long Term Debt141332
Short Term Debt13417
Minority Interest0115
Trade Payables55815
Others Liabilities 141122
Total Liabilities 136288155

Fixed Assets

Net Fixed Assets +132144
Gross Block242357
Accumulated Depreciation11214
CWIP 0542
Investments 03411
Inventories471328
Trade Receivables5121328
Cash Equivalents 01472
Others Assets 3182641
Total Assets 136288155
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + -0-192-10
PBT 37914
Adjustment 0007
Changes in Working Capital -4-25-4-26
Tax Paid 0-1-2-5
Cash Flow From Investing Activity + -0-10-20-14
Capex -0-7-18-11
Net Investments 0-3-0-9
Others 01-26
Cash Flow From Financing Activity + 1421120
Net Proceeds from Shares 3510
Net Proceeds from Borrowing -336916
Interest Paid -0-0-1-4
Dividend Paid 0000
Others 1227
Net Cash Flow 014-7-4
PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)83.2324.2112.5218.78
ROCE (%)43.2123.615.3219.17
Asset Turnover Ratio1.690.840.60.72
PAT to CFO Conversion(x)-0-3.170.33-1
Working Capital Days
Receivable Days83.3098.20104.4086.30
Inventory Days62.2062.7080.8085.70
Payable Days177.30111.7090.80110.90

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Trident Lifeline Ltd FAQs

The current trading price of Trident Lifeline on 23-Sep-2026 11:42 is ₹392.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Trident Lifeline stood at ₹484.0 Cr

The latest P/E ratio of Trident Lifeline as of 22-Sep-2026 is 26.75.

The latest P/B ratio of Trident Lifeline as of 22-Sep-2026 is 4.79.

The 52-week high of Trident Lifeline is ₹421.0 and the 52-week low is ₹229.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Trident Lifeline is ₹102 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Trident Lifeline Ltd is a below average quality company.

The key valuation ratios of Trident Lifeline Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Trident Lifeline Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Trident Lifeline Ltd

The Company was originally incorporated as “Trident Lifeline Private Limited” as a Private Limited Company under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 09, 2014, issued by the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Subsequently, the Company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the Company held on June 02, 2022 and the name of the Company was changed to “Trident Lifeline Limited”. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company dated June 10, 2022 was issued by the Registrar of Companies, Ahmedabad.

Trident Lifeline is engaged in the pharmaceutical business ethical marketing in domestic as well as international market. It is also engaged in distribution of pharmaceutical products through third party distribution network. It offers wide range of pharmaceutical formulations and products manufactured on contract manufacturing under loan lisence. It operates in India as well as African, Latin American and East Indian Countries. It has its presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanamar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, Venuzela.

The company is engaged in the business of marketing pharmaceutical products. For which it has obtain necessary approvals from FDA for getting the formulations manufacture from contract manufacturers on Loan License or on principle-to-principle basis. It also takes the necessary Trademark approvals & registrations wherever required. Its Pharma business operations are supported by various contract manufacturers having facilities which are approved by FDA/WHO and other relevant authorities. It typically works on contract manufacturing basis or at times purchase order basis, depending upon customer’s requirement, with manufacturer of pharma products. Presently the company operates with one contract manufacturer. The company has maintained relationship with the regular supplier, having FDA and WHO approved plant to supply pharma formulations. These units manufacture tablets, capsules, dry powder, syrup under its own brands.

Business area of the company

The company is engaged in the manufacturing and marketing of quality finished dosages. It is one of the fastest growing pharmaceutical companies in the SME segment providing unprecedented quality of healthcare products. It deals in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. Its product portfolio comprises of vide range of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steriodal anti-inflamatory drug (NSAIDS).

You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now